Key result
Malondialdehyde-modified protein colocalizes with extracellular apolipoprotein B-100 in atheroma of hyperlipidemic rabbits.
Answers are grounded in this paper and cite their sources.
It has been proposed that chemically reactive lipids released during lipid peroxidation convert low density lipoprotein (LDL), the major carrier of plasma cholesterol, to an abnormal form and that receptor-mediated clearance of this altered LDL produces cholesteryl ester deposition in macrophage-derived foam cells of atheroma. Immuno-cytochemical analyses now reveal the presence of protein modified by malondialdehyde, a peroxidative end product, which colocalizes with the extracellular deposition of apolipoprotein B-100 protein of LDL in atheroma from Watanabe heritable hyperlipidemic rabbits. These findings provide direct evidence for the existence in vivo of protein modified by a physiological product of lipid peroxidation within arterial lesions.
No takes yet. Share an insight, caveat, or question.
Haberland et al. (1988) studied Atheroma in Watanabe heritable hyperlipidemic rabbits. Immuno-cytochemical analysis of malondialdehyde-modified protein was evaluated on Presence of malondialdehyde-modified protein colocalizing with apolipoprotein B-100 in atheroma. Immuno-cytochemical analysis revealed malondialdehyde-modified protein colocalizing with extracellular apolipoprotein B-100 of LDL in atheroma of hyperlipidemic rabbits.
Synapse has enriched 10 related papers. Consider them for comparative context: